» Authors » Laura Pasetto

Laura Pasetto

Explore the profile of Laura Pasetto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 462
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Bonetto V, Pasetto L, Lisi I, Carbonara M, Zangari R, Ferrari E, et al.
Front Immunol . 2023 Jan; 13:1070379. PMID: 36591311
Background: Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is associated with disorders affecting the peripheral and the central nervous system. A high number of patients develop post-COVID-19 syndrome with...
12.
Violatto M, Pasetto L, Casarin E, Tondello C, Schiavon E, Talamini L, et al.
Cells . 2022 Dec; 11(24). PMID: 36552768
The development of nanoparticles (NPs) to enable the passage of drugs across blood-brain barrier (BBB) represents one of the main challenges in neuropharmacology. In recent years, NPs that are able...
13.
Beghi E, Pupillo E, Bianchi E, Bonetto V, Luotti S, Pasetto L, et al.
Eur J Neurol . 2022 Sep; 30(1):69-86. PMID: 36148821
Background And Purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal...
14.
Pasetto L, Grassano M, Pozzi S, Luotti S, Sammali E, Migazzi A, et al.
Brain . 2021 Dec; 144(12):3710-3726. PMID: 34972208
Aggregation and cytoplasmic mislocalization of TDP-43 are pathological hallmarks of amyotrophic lateral sclerosis and frontotemporal dementia spectrum. However, the molecular mechanism by which TDP-43 aggregates form and cause neurodegeneration remains...
15.
Fabbrizio P, DAgostino J, Margotta C, Mella G, Panini N, Pasetto L, et al.
Cell Mol Life Sci . 2021 Dec; 79(1):7. PMID: 34936028
Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder that leads to progressive degeneration of motor neurons and severe muscle atrophy without effective treatment. Most research on the disease has been...
16.
Pasetto L, Callegaro S, Corbelli A, Fiordaliso F, Ferrara D, Brunelli L, et al.
Mol Neurodegener . 2021 Aug; 16(1):52. PMID: 34376243
Background: Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem motor neuron disease for which currently there is no effective treatment. There is an urgent need to identify biomarkers to tackle...
17.
Vallarola A, Tortarolo M, De Gioia R, Iamele L, de Jonge H, de Nola G, et al.
Int J Mol Sci . 2020 Nov; 21(22). PMID: 33198383
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease with no effective treatment. The Hepatocyte Growth Factor/Scatter Factor (HGF/SF), through its receptor MET, is one of the most potent survival-promoting...
18.
Aquila G, Re Cecconi A, Forti M, Frapolli R, Bello E, Novelli D, et al.
Cancers (Basel) . 2020 Aug; 12(8). PMID: 32824440
Trabectedin (ET743) and lurbinectedin (PM01183) limit the production of inflammatory cytokines that are elevated during cancer cachexia. Mice carrying C26 colon adenocarcinoma display cachexia (i.e., premature death and body wasting...
19.
Luotti S, Pasetto L, Porcu L, Torri V, Elezgarai S, Pantalone S, et al.
Neurobiol Dis . 2020 Feb; 139:104815. PMID: 32087285
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease for which there are no validated biomarkers. Previous exploratory studies have identified a panel of candidate protein biomarkers in peripheral...
20.
Bouybayoune I, Comerio L, Pasetto L, Bertani I, Bonetto V, Chiesa R
Neurobiol Dis . 2019 Jun; 130:104498. PMID: 31181281
Prion diseases typically involve brain deposition of abnormally folded prion protein, which is associated with activated glia and increased cytokine production. Cyclophilin A (CypA) is a ubiquitous protein with peptidyl...